Physician profile
Jeffrey M Craft
NPI 1497936231
$5,458.48
in general payments reported to CMS, 2019-2025
46 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 84% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $258 · 2021: $390 · 2022: $915 · 2023: $976 · 2024: $1,052 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,089.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $494.91 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $473.34 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $449.76 | 2022-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $350.94 | 2019-2025 | Imfinzi, Tagrisso, Calquence |
| Gt Medical Technologies, INC | $324.68 | 2023-2025 | Gammatile, Gammatile |
| Novocure INC. | $310.30 | 2019-2025 | Optune, Optune Gio |
| Eisai INC. | $249.75 | 2021-2025 | |
| Emd Serono, INC. | $237.06 | 2019-2025 | Bavencio |
| Genzyme Corporation | $211.00 | 2019-2025 | |
| Amgen INC. | $199.91 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Janssen Biotech, INC. | $176.56 | 2019-2025 | Darzalex, Talvey, Erleada |
| Sumitomo Pharma America, INC. | $164.32 | 2023-2025 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $161.15 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $155.15 | 2021-2023 | Prolaris |
| Mevion_medical_systems_inc | $143.49 | 2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accuray Incorporated | $141.68 | 2019 | |
| Daiichi Sankyo INC. | $135.74 | 2022-2024 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $123.91 | 2022-2025 | Iclusig, Fruzaqla, Alunbrig |
| Abbvie INC. | $86.78 | 2019-2023 | Venclexta |
| Beigene USA, INC. | $79.99 | 2024-2025 | Tevimbra, Brukinsa |
| Kyowa Kirin, INC. | $71.31 | 2019-2023 | Poteligeo |
| Seagen INC. | $59.84 | 2020-2023 | Padcev |
| Incyte Corporation | $55.24 | 2024-2025 | Pemazyre, Monjuvi, Jakafi |
| Karl Storz Endoscopy-America | $52.98 | 2019 | |
| Taiho Oncology, INC. | $46.83 | 2021-2024 | |
| Lilly USA, LLC | $45.50 | 2022-2024 | Jaypirca |
| Pharmacyclics LLC, An Abbvie Company | $44.13 | 2019-2023 | Imbruvica |
| Beone Medicines USA, INC. | $39.19 | 2025 | Brukinsa, Tevimbra |
| Boston Scientific Corporation | $37.80 | 2024-2025 | Spaceoar Vue System - 10ml |
| Pfizer INC. | $32.72 | 2019-2024 | |
| Aveo Pharmaceuticals, INC. | $32.39 | 2021-2024 | |
| Sobi, INC | $29.96 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $25.75 | 2022 | |
| Exelixis INC. | $22.38 | 2023 | Cabometyx |
| Tolmar, INC. | $18.11 | 2023 | |
| Glaxosmithkline, LLC. | $17.86 | 2020 | |
| Stemline Therapeutics INC. | $17.82 | 2023 | Orserdu |
| Progenics Pharmaceuticals, INC. | $17.81 | 2022 | |
| Amag Pharmaceuticals, INC. | $17.67 | 2021 | |
| Tesaro, INC. | $17.59 | 2019 | |
| Morphosys, US INC. | $17.15 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $15.73 | 2019 | |
| Mission Pharmacal Company | $13.87 | 2019 | |
| Mirati Therapeutics, INC. | $13.32 | 2023 | Krazati |
| Puma Biotechnology, INC. | $12.94 | 2023 | |
| Agios Pharmaceuticals, INC. | $12.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Craft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.